19946027

Source:http://linkedlifedata.com/resource/pubmed/id/19946027

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019080, umls-concept:C0032143, umls-concept:C0271084, umls-concept:C0796392, umls-concept:C2699708
pubmed:issue	1
pubmed:dateCreated	2010-4-13
pubmed:abstractText	To evaluate the efficacy and safety of pars plana vitrectomy (ppV) with subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab, and fluid-gas exchange for neovascular age-related macular degeneration (AMD) with submacular haemorrhage (SMH).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19946027-20870640
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0421041
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1468-2079
pubmed:author	pubmed-author:HillenkampJJ, pubmed-author:KlattCC, pubmed-author:RoiderJJ, pubmed-author:TreumerFF
pubmed:issnType	Electronic
pubmed:volume	94
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	48-53
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:19946027-Aged, pubmed-meshheading:19946027-Aged, 80 and over, pubmed-meshheading:19946027-Angiogenesis Inhibitors, pubmed-meshheading:19946027-Antibodies, Monoclonal, pubmed-meshheading:19946027-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19946027-Choroidal Neovascularization, pubmed-meshheading:19946027-Combined Modality Therapy, pubmed-meshheading:19946027-Drug Therapy, Combination, pubmed-meshheading:19946027-Female, pubmed-meshheading:19946027-Fibrinolytic Agents, pubmed-meshheading:19946027-Humans, pubmed-meshheading:19946027-Intraoperative Complications, pubmed-meshheading:19946027-Macular Degeneration, pubmed-meshheading:19946027-Male, pubmed-meshheading:19946027-Postoperative Complications, pubmed-meshheading:19946027-Recombinant Proteins, pubmed-meshheading:19946027-Retinal Hemorrhage, pubmed-meshheading:19946027-Retrospective Studies, pubmed-meshheading:19946027-Tissue Plasminogen Activator, pubmed-meshheading:19946027-Visual Acuity, pubmed-meshheading:19946027-Vitrectomy
pubmed:year	2010
pubmed:articleTitle	Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.
pubmed:affiliation	Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Str 3, Haus 25, D-24105 Kiel, Germany.
pubmed:publicationType	Journal Article, Evaluation Studies